If your cycles are regular and you are still not pregnant, Clomid can look like an easy way to tip the odds. The label and the major fertility guidelines say otherwise for most people in that position: on its own, with timed sex, clomiphene does not improve the chance of pregnancy in unexplained infertility, and it still carries its usual risks.
The latest restatement came from the UK. On March 31, 2026, the National Institute for Health and Care Excellence (NICE) published guideline NG257, which replaces its 2013 fertility guideline CG156. Recommendation 1.38.2 reads: “Do not offer ovarian stimulation as a stand-alone treatment for unexplained fertility problems.” In its rationale, the committee wrote that “ovarian stimulation alone is not effective or cost effective.”
US guidance reached a similar conclusion earlier. The American Society for Reproductive Medicine (ASRM) 2020 guideline on unexplained infertility states: “It is not recommended to use clomiphene citrate with timed intercourse as a treatment for unexplained infertility,” and explains that it is no more effective than expectant management, meaning continuing to try without treatment.
Neither guideline says clomiphene has no place for people who ovulate. Both leave room for stimulation combined with intrauterine insemination (IUI), and the details differ. That distinction is the core of this article.
What each source says
| Source | Recommendation or label wording | Year |
|---|---|---|
| Clomid FDA label | “Indicated for the treatment of ovulatory dysfunction in women desiring pregnancy” and “indicated only in patients with demonstrated ovulatory dysfunction” | Label version on DailyMed, 2025 |
| ASRM Practice Committee | Clomiphene with timed intercourse not recommended for unexplained infertility (evidence B, moderate recommendation) | 2020 |
| ASRM Practice Committee | Clomiphene with IUI recommended for couples with unexplained infertility (evidence A, strong recommendation); typically 3 or 4 cycles of stimulation and IUI with oral agents, then IVF if unsuccessful | 2020 |
| ESHRE guideline (Europe) | IUI with ovarian stimulation recommended as first-line treatment for unexplained infertility (strong, very low-quality evidence) | 2023 |
| NICE NG257 (UK) | Try to conceive for a total of 2 years before treatment; do not offer ovarian stimulation as a stand-alone treatment; then consider up to 4 cycles of IUI with gonadotrophin stimulation, or offer IVF | 2026 |
Two points stand out. First, everyone agrees on the narrow question in the title: clomiphene plus timed sex is not an evidence-based fix for unexplained infertility. Second, they part ways on what comes next. ASRM recommends oral agents such as clomiphene with IUI, while NICE now points toward IUI with injected gonadotrophins or straight to IVF. US clinics generally follow ASRM; the NICE guidance is written for the UK health system.
Why the label is written around ovulation problems
Clomiphene works by triggering the hormonal chain that leads to ovulation. The label describes it as “a useful therapy for the anovulatory patient desiring pregnancy,” and lists the groups most likely to succeed, including people with polycystic ovary syndrome and several forms of absent periods. It also states that impediments to pregnancy “must be excluded or adequately treated” before starting, naming thyroid disorders, adrenal disorders, high prolactin and male factor infertility.
If you already release an egg each month, the main problem the drug was approved to fix is not present. The label does not discuss use in people who ovulate normally. Use outside the indication, as with clomiphene plus IUI in unexplained infertility, is a clinical decision a fertility specialist makes with monitoring, not something the label endorses.
The risks do not shrink because you ovulate
The label’s warnings apply to anyone taking the drug. For someone whose ovaries already respond normally, extra stimulation is the point of treatment and the source of the main hazards.
- Multiple pregnancy. In clinical investigations described on the label, 7.98% of reported pregnancies were multiple: 6.9% twins, 0.5% triplets, 0.3% quadruplets and 0.1% quintuplets. The label also warns of a higher chance of tubal pregnancy, including a tubal pregnancy alongside one in the uterus. ASRM reports multiple pregnancy rates of 0 to 12.5% with clomiphene and IUI.
- Ovarian enlargement and OHSS. Ovarian enlargement was the most common adverse event in clinical studies, at 13.6%. Ovarian hyperstimulation syndrome (OHSS) has been reported and “may progress rapidly (within 24 hours to several days).” Early warning signs listed are abdominal pain and swelling, nausea, vomiting, diarrhea and weight gain.
- Visual symptoms. Blurring, spots or flashes can occur. They become more common with higher total dose or longer use and are usually reversible, but the label says they may be prolonged or irreversible, and anyone with visual symptoms should stop and have a prompt eye examination.
- Everyday effects. Hot flushes affected 10.4% of patients in clinical studies, and abdominal or pelvic discomfort or bloating 5.5%.
- Long-term use. The label says long-term cyclic therapy is not recommended beyond a total of about six cycles, and that prolonged use may increase the risk of a borderline or invasive ovarian tumor.
People who are pregnant, have liver disease or past liver dysfunction, abnormal uterine bleeding without a known cause, ovarian cysts or enlargement not due to PCOS, uncontrolled thyroid or adrenal disease, or an intracranial lesion such as a pituitary tumor. The label also requires a pelvic exam before the first and each later course.
Our articles on clomiphene monitoring and multiple-pregnancy risk and letrozole vs. Clomid explain how clinics track response and why some prefer letrozole for certain patients. ASRM’s 2020 guideline also does not recommend letrozole with timed intercourse for unexplained infertility.
If clomiphene is part of your plan
When a specialist does recommend clomiphene, for example with IUI, the label describes safeguards worth knowing about. A pelvic examination is required before the first course and before each later course. If an ovary enlarges, the label says no further clomiphene should be given until the ovaries return to their pretreatment size, and it notes that maximal enlargement may not occur until several days after the last tablet. That is why pain or bloating a few days after finishing a course still deserves a call.
The label also warns that visual symptoms can make driving or operating machinery more hazardous, particularly in changing light, and asks patients to tell the physician about any unusual visual symptoms. ASRM’s guideline frames clomiphene with IUI as a time-limited step, typically 3 or 4 cycles, followed by IVF for those who do not conceive. Asking at the start what the stopping point is helps avoid drifting into the long-term use the label advises against.
Why some people end up taking it anyway
Clomiphene is inexpensive and taken by mouth, and many people have a friend who conceived on it. Some are offered it by a general clinician before a full workup, and some find tablets sold online without a prescription. A friend’s success usually reflects a different diagnosis: if she did not ovulate before, the drug was fixing her specific problem. Taking clomiphene without a prescription also means taking it without the pelvic exams and monitoring the label calls for. If someone offers you tablets without a prescription, talk to a clinician before taking anything.
A regular cycle also does not mean everything has been checked. The label’s own list of impediments, from thyroid problems to male factor infertility, applies here. Ask what an evaluation would cover for both partners; our infertility overview describes common causes, tests and when to seek help.
Your situation, and the question to ask
| Your situation | Question to ask your clinician |
|---|---|
| Regular cycles, no infertility evaluation yet | Should we complete an evaluation for both partners, including a semen analysis, before any medicine? |
| Offered clomiphene with timed sex for unexplained infertility | The ASRM guideline does not recommend this. What is the reason in my case, and what are the alternatives? |
| Offered clomiphene with IUI | How many cycles are planned, how will you monitor my ovaries, and what happens if I respond with several follicles? |
| Cycles look regular but ovulation has never been confirmed | Can we confirm I actually ovulate before deciding whether I have an ovulation problem? |
| Already had several clomiphene cycles without pregnancy | The label advises against long-term use beyond about six cycles. Is it time to reassess the plan? |
| History of ovarian cysts, liver disease, unexplained bleeding or eye problems | Does anything on the label’s contraindication list apply to me? |
| Strongly want to avoid twins | What is my realistic multiple-pregnancy risk with this plan, and what would you do if too many follicles develop? |
| Thinking of buying tablets online | What would I miss by skipping monitoring, and is there a safer route for my situation? |
What remains uncertain
The guidelines agree on clomiphene with timed sex but not on what should come next, and much of the evidence behind all of them is limited. ESHRE graded its own first-line recommendation as resting on very low-quality evidence, and NICE’s 2026 shift toward gonadotrophin IUI or IVF is partly a cost-effectiveness judgment for the UK system. For a person who ovulates regularly, the practical message is narrower: clomiphene is not a general fertility booster, and any plan that includes it should come from a full evaluation and a clinician who will monitor each cycle.
Sources
- DailyMed: Clomid (clomiphene citrate) label
- ASRM Practice Committee: Evidence-based treatments for couples with unexplained infertility (2020)
- Fertil Steril 2020;113(2):305-322, PubMed record
- NICE NG257 (2026): Unexplained fertility problems
- NICE NG257: Rationale and impact
- ESHRE evidence-based guideline: unexplained infertility (2023)
Evidence checked November 2, 2026. General information only; fertility treatment decisions belong with a clinician who can examine and monitor you.